Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVMZ


Primary Symbol: PAVM

Healthcare Medical Devices
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

PR Newswire August 8, 2024

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

PR Newswire August 6, 2024

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PR Newswire August 5, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024

PR Newswire July 30, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

PR Newswire July 29, 2024

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

PR Newswire July 23, 2024

Lucid Diagnostics Launches New Corporate Website

PR Newswire July 11, 2024

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PR Newswire July 2, 2024

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

PR Newswire June 13, 2024

4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing

PR Newswire June 12, 2024

PAVmed Provides Business Update and First Quarter 2024 Financial Results

PR Newswire May 13, 2024

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

PR Newswire May 13, 2024

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

PR Newswire May 9, 2024

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

PR Newswire May 7, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

PR Newswire May 3, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

PR Newswire May 2, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

PR Newswire May 2, 2024

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

PR Newswire April 30, 2024

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

PR Newswire April 29, 2024

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire April 8, 2024